Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study probes metabolism in ALS for hidden clues

NCT ID NCT03984708

Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how metabolism differs in people with ALS. Researchers took blood and skin samples from 9 patients to analyze molecules and genes. The goal was to better understand the disease, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could reveal new metabolic targets for future ALS treatments.
What could go wrong
This is a very small, early-stage observational study with only 9 participants. It does not test any treatment, so it may not lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Started

Jan 2020

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Case group selection criteria: Inclusion Criteria: * Age ≥ 18 years and ≥ 75 years * ALS according to the El Escorial criteria * Diagnosis of ALS \< 6 months * Symptoms onset \< 2 years * Patients affiliated to social security scheme * Informed consent signed by the patient Exclusion Criteria: * Pregnant or breastfeeding women * Contraindication to biopsy * Contraindication to local anesthesia * Treatment with oral or injectable anticoagulants, antiplatelet (except aspirin) * Unbalanced Diabetes * Systemic corticosteroid treatment * Dermatological diseases of the fibroblast * Skin cancer * Protection measure for guardianship or curatorship Control group selection criteria: Inclusion Criteria: * Age ≥ 18 years and ≥ 75 years * No neuronal disease * Patients affiliated to social security scheme * Informed consent signed by the patient Exclusion Criteria: * Pregnant or breastfeeding women * Contraindication to biopsy * Treatment with oral or injectable anticoagulants, antiplatelet (except aspirin) * Unbalanced Diabetes * Systemic corticosteroid treatment * Dermatological diseases of the fibroblast * Skin cancer * Protection measure for guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyotrophic lateral sclerosis

Contacts and locations

Locations

  • Neurology Department, University Hospital, Limoges

    Limoges, 87042, France

  • Neurology Department, University Hospitla, Tours

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.